Rapport Therapeutics, Inc.
RAP-219
focal onset seizures
Countdown
358days
Catalyst readout · ~ Jun 30, 2027 estimated
What's at stake
A key catalyst for RAP-219 (focal onset seizures) is expected ~ Jun 30, 2027.
Primary source
· SEC 8-K
verified 14h ago
“Outside of FOS, Rapport is conducting a Phase 3 trial in primary generalized tonic-clonic seizures is expected to begin in the first half of 2027.”